Latest Period
Q4 2025
Security Snapshot
NRX Pharmaceuticals, Inc. - Common Stock, $0.001 par value (NRXP) Institutional Ownership
CUSIP: 629444209
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
28
Shares (Excl. Options)
5,235,517
Price
$2.71
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, $0.001 par value
- Symbol
- NRXP on Nasdaq
- Shares outstanding
- 23,771,791
- Price per share
- $2.13
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 5,235,517
- Total reported value
- $14,169,868
- % of total 13F portfolios
- 0%
- Share change
- +1,263,887
- Value change
- +$3,242,026
- Number of holders
- 28
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- NRXP - NRX Pharmaceuticals, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 629444209.
- 28 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 28 to 3 between Q4 2025 and Q1 2026.
- Reported value moved from $14,169,868 to $883,805.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 28 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 629444209?
CUSIP 629444209 identifies NRXP - NRX Pharmaceuticals, Inc. - Common Stock, $0.001 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 629444209:
Significant Owners of NRX Pharmaceuticals, Inc. - Common Stock, $0.001 par value (NRXP) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| B Group, Inc. | 13% | $8,820,000 | 3,000,000 | The B Group, Inc. | 18 Aug 2025 | |||
| Anson Funds Management LP | 9.3% | +33% | $5,151,970 | +$1,367,184 | 1,604,975 | +36% | Anson Funds Management LP | 30 Jun 2025 |
As of 31 Dec 2025, 28 institutional investors reported holding 5,235,517 shares of NRX Pharmaceuticals, Inc. - Common Stock, $0.001 par value (NRXP). This represents 22% of the company’s total 23,771,791 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of NRX Pharmaceuticals, Inc. - Common Stock, $0.001 par value (NRXP) together control 22% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Anson Funds Management LP | 13% | 3,043,957 | +50% | 1.2% | $8,249,123 |
| VANGUARD GROUP INC | 3.1% | 729,842 | +36% | 0% | $1,977,871 |
| COMMONWEALTH EQUITY SERVICES, LLC | 1.5% | 366,631 | 0% | $993,570 | |
| AdvisorShares Investments LLC | 1.4% | 328,004 | -4.1% | 0.15% | $888,891 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.92% | 218,866 | +18% | 0% | $593,212 |
| Bleakley Financial Group, LLC | 0.49% | 117,204 | 0.01% | $317,623 | |
| STATE STREET CORP | 0.37% | 86,984 | +14% | 0% | $235,727 |
| BlackRock, Inc. | 0.35% | 82,654 | +26% | 0% | $223,992 |
| Global Retirement Partners, LLC | 0.17% | 39,300 | 0% | $106,503 | |
| JANE STREET GROUP, LLC | 0.16% | 38,065 | -48% | 0% | $103,156 |
| One Wealth Management Investment & Advisory Services, LLC | 0.16% | 37,873 | +35% | 0.11% | $102,636 |
| Chicago Partners Investment Group LLC | 0.14% | 33,421 | -20% | 0% | $72,524 |
| NORTHERN TRUST CORP | 0.12% | 28,947 | +1.2% | 0% | $78,446 |
| TWO SIGMA INVESTMENTS, LP | 0.07% | 17,436 | -67% | 0% | $47,252 |
| Point72 Asset Management, L.P. | 0.07% | 15,979 | 0% | $43,303 | |
| SJBENEN ADVISORY, LLC | 0.06% | 15,000 | 0% | 0.06% | $40,650 |
| Ethos Financial Group, LLC | 0.05% | 11,900 | 0% | 0% | $32,249 |
| MORGAN STANLEY | 0.04% | 10,029 | -9.5% | 0% | $27,179 |
| UBS Group AG | 0.01% | 3,538 | -98% | 0% | $9,588 |
| BANK OF AMERICA CORP /DE/ | 0.01% | 3,239 | -4.7% | 0% | $8,777 |
| SBI Securities Co., Ltd. | 0.01% | 2,500 | 0% | 0% | $6,775 |
| ROYAL BANK OF CANADA | 0.01% | 2,000 | 0% | $5,000 | |
| WELLS FARGO & COMPANY/MN | 0.01% | 2,000 | 0% | 0% | $5,420 |
| OSAIC HOLDINGS, INC. | 0% | 90 | -92% | 0% | $243 |
| JPMORGAN CHASE & CO | 0% | 34 | 0% | 0% | $92 |
Institutional Holders of NRX Pharmaceuticals, Inc. - Common Stock, $0.001 par value (NRXP) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 414,931 | $883,805 | +$65,604 | $2.13 | 3 |
| 2025 Q4 | 5,235,517 | $14,169,868 | +$3,242,026 | $2.71 | 28 |
| 2025 Q3 | 3,956,630 | $13,043,325 | +$3,167,783 | $3.30 | 24 |
| 2025 Q2 | 2,994,368 | $9,761,438 | +$2,410,566 | $3.26 | 25 |
| 2025 Q1 | 2,260,524 | $4,602,262 | +$2,464,504 | $2.05 | 22 |
| 2024 Q4 | 1,048,642 | $2,306,847 | +$754,487 | $2.20 | 25 |
| 2024 Q3 | 714,327 | $1,207,232 | +$328,214 | $1.69 | 18 |
| 2024 Q2 | 510,346 | $1,261,065 | +$1,261,065 | $2.44 | 18 |